# Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

> **NCT03265145** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 714 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Stiolto Respimat
- **DRUG:** ICS (Inhaled Corticosteroid) (Triple therapy)
- **DRUG:** LABA (Long-Acting Beta Agonist) (Triple therapy)
- **DRUG:** LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)

## Key facts

- **NCT ID:** NCT03265145
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-20
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 714 (ACTUAL)
- **Last updated:** 2022-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03265145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03265145, "Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03265145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*